We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
British generic drugmakers want branded generics to be exempt from any further price cuts on brand pharmaceuticals, arguing their products already deliver greater savings than what can be achieved from government intervention. Read More
Specialty and generic drug maker Actavis has agreed to buy botox manufacturer Allergan for $66 billion in a move analysts say could help transform Actavis into a major pharma giant. Read More
The FDA chided drugmaker Sciecure Pharma for distributing a sales aid that touted overblown superiority claims and disregarded risk information surrounding its insomnia treatment Doral.
Read More
The drug pricing authority of India is calling on industry, public health experts and others to help update the country’s list of life-saving and essential drugs, a move that one observer says is needed to understand which drugs are on the market and under price controls. Read More
The FDA wants to know how a spouse may influence a partner’s perception of a direct-to-consumer drug advertisement, the second study examining a specific DTC ad scenario that the agency has announced this week. Read More
A federal judge has finalized an agreement by Pfizer to pay $325 million to settle claims it marketed off-label uses of its epilepsy drug Neurontin. Read More
The Office of the U.S. Trade Representative is conducting a review of India’s intellectual property regime that focuses in large part on pharma IP issues, including access to affordable medicines. Read More
Pharmaceutical intellectual property rights remain a significant sticking point in a proposed draft of the massive Trans-Pacific Partnership trade pact leaked in October. Read More
The Justice Department has launched a probe into potential anticompetitive practices of the generic drug industry, adding more scrutiny to generic drug pricing that already is under investigation by Congress. Read More